Logiscreen

Esperion Therapeutics Inc

$3.13
Market Cap 803.82M
ROE 2.0%
Gross Margin 56.8%
Debt/Equity -1.8
Current Ratio 1.5
Revenue QoQ 23.2%
EPS QoQ -0.5%
F-Score 1

About

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work.

Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-108.29
vs median 33.61
P/B
-2.61
vs median 2.16
ROE
0.02
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics